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The effectiveness of breast screening in women aged 50–64 has
been well established by randomised trials, and recent analyses
have shown that screening in women aged 65–69 is probably as
effective in terms of reducing mortality from breast cancer as
screening in women aged 50–64 (Chen et al, 1995). 
The report of the Forrest committee (Forrest, 1986) in 1986,
which led to the implementation of the NHS Breast Screening
Programme in the United Kingdom, recommended that women
aged 50–64 be invited for screening every 3 years, with women
aged 65 and over being able to self-refer. The main reason for this
distinction was concern over possible lower acceptance rates
among older women, together with possible reduced cost-
effectiveness due to decreased life expectancy in older women. 
Population screening in a number of countries includes women
up to age 69 or 70 (Shapiro et al, 1998). Some demonstration
studies of inviting older women also showed that their uptake was
only slightly lower than that for 50–64 year olds from the same
locality, implying that reasonable uptakes could be achieved
across the NHS as a whole (Hobbs et al, 1990; Hendry and
Entwhistle, 1996; Horton-Taylor et al, 1996). The number of self-
referrals in women aged 65 and over had increased to 65 032 by
1998/9, 44 811 of these being aged 65–69. 
Demonstration studies at 3 sites were established by the
Department of Health to determine the implications of extending
the NHS Breast Screening Programme to women aged 65–69 by
including this age-group in the routine invitation system. Findings
from one of the sites after one year have previously been reported
(Rubin et al, 1998). This paper presents the results of the
evaluation of the full 3 years of all 3 sites. Decisions on the exten-
sion of the programme have been made on the basis of the results
of these studies. 
METHODS 
The demonstration studies were scheduled to run for 3 years at
each of 3 sites, with appointments for women aged 65–69 inter-
mingled with those of women aged 50–64 and self-referrals of
older women. As for women aged 50–64, those aged 65–69 were
sent by post an invitation to attend at a specific date/time for
mammographic screening. Those with an abnormality detected on
the mammogram were sent an appointment for further assessment,
which could include clinical examination, further mammographic
views and ultrasound. 
East Sussex, Brighton and Hove began screening for the study
in May 1996, Nottingham in February 1997 and Leeds and
Wakefield in April 1997. This timing means that women aged
65–67 had mostly been invited 3 years previously in the most
recent screening round, but those aged 68–69 had mostly missed a
round and would have been last invited 6 years previously. 
The principal screening process and outcome measures were
already routinely recorded at each demonstration site as part of the
NHSBSP; these measures were analysed by age and time since last
screen. Comparisons with equivalent data for the whole of
England for the age-group 50–64 have been made to determine the
representativeness of the demonstration sites. 
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doi: 10.1054/ bjoc.2001.2047, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn addition, pathology data were obtained from all 3 sites on the
size, lymph node status and grade of screen-detected cancers in
both younger and older women during the study period. 
The Nottingham Prognostic Index (NPI) (Galea et al, 1992) was
calculated from the available data using the formula: size (cm) ×
0.2 + lymph node status (1–3) + grade. This index has been
constructed and used to define 3 subsets of breast cancer patients
up to age 70 with different prognosis. An index using a revised
formula: size (cm) × 0.7 + grade for cases with unknown lymph
node status was also calculated (Pinder S, Duffy S, personal
communication). 
The costs of an invitation, screen and assessment associated
with breast screening in the UK setting estimated previously for
women aged 50–64 for one-view mammography (Johnston et al,
1998) were used to form the basis of the unit cost estimates for
women aged 65–69, uprated to 1999/2000 prices (NHS Executive,
1997) and to take account of the fact that a small proportion of
women have more than one assessment visit (Johnston et al,
1996). 
Data on the proportion of technical recall screens were available
from all 3 sites. The cost of a technical recall was assumed to be
the average of the cost of a screen taken on a mobile van and static
unit. 
To study possible variation in invitation costs with age, a survey
was conducted to log telephone queries and appointment changes
at each of the demonstration sites for all women aged 50–69 for
one week each month over a period of a year, and the proportion in
each age-group was calculated using a denominator estimated
from the total number of women invited during the year. 
If older women are less mobile and take longer to screen, this
would affect throughput. Screening times and overall times spent
in the unit were therefore measured for women aged 50–64 and
65–69 at each of the 3 demonstration sites, on a consecutive series
of women until at least 50 women aged 65–69 had been screened.
The timings took place at a mix of mobile and static sites during
the winter months when the women were expected to be wearing
more clothing. 
The proportion of women assessed who had FNA cytology
and/or core biopsy in the 2 age-groups was compared using data
from standard returns. All other assessment procedures were
assumed to be the same for both age-groups. 
To estimate total costs, the numbers invited, screened and
assessed in each age group for women previously screened were
used, since in an extension to the programme the majority of
women aged 65–69 would be in this category. The numbers
invited, screened and assessed were summed across the 3 sites and
multiplied by the respective unit cost. The effect of using figures
for all women invited for screening (regardless of previous
screening history), or of using those for women screened less than
or equal to 5 years ago was addressed in the sensitivity analysis. 
RESULTS 
Overall uptake in women aged 65–69 was 71%. Table 1 shows the
uptake of screening by age (50–64 and 65–69) according to type of
invitation. Results for England for women aged 50–64 for April
1997 to March 2000 are included for comparison. Uptake in
previous non-attenders within the NHSBSP is generally low, and
this was also observed in the demonstration studies. (A small
percentage of women aged 65–69 were reported as receiving their
first invitation; this may be due to women moving into a district
whose previous screening history had not been added to the
computer system.) 
For women previously screened within 5 years, uptake both in
women 50–64 and 65–69 was high (91% and 90% respectively).
For women with a screen more than 5 years previously, uptake was
higher in women aged 65–69 (77%) than in those aged 50–64
(58%), reflecting the fact that many of the older women would not
have been invited for 6 years, whereas the younger women would
have been non-attenders at a previous invitation. Whilst there was
variation in uptake levels between sites, with higher uptake in
Nottingham and East Sussex, Brighton and Hove than in Leeds
and Wakefield, the pattern was similar in all 3 sites. 
Table 2 gives the outcomes of screening for the 3 sites combined
for those women with a previous screen. Rates of referral for assess-
ment were significantly lower in women aged 65–69 than in those
aged 50–64 (P < 0.0001, P = 0.04 for women screened ≤ 5 years ago
and >5 years ago, respectively). For each age category, referral rates
were higher for women with a longer screening interval. 
Invasive cancer detection rates were higher in women 65–69
than in those 50–64: 0.67% vs 0.41% for those previously
screened within 5 years (P < 0.0001) and 0.71% versus 0.56% for
those with a longer screening interval (NS, P = 0.26). The rates in
women aged 65–69 were also higher than in those aged 60–64. 
In-situ cancer detection rates were similar across age-groups
for women screened within 5 years. For women with a longer
screening interval comparison was difficult due to small numbers. 
Uptake and outcome of screening of women aged 50–64 were
similar to those for England as a whole, suggesting that
the demonstration sites were representative of the national
programme. There was no evidence of systematic differences
between the results for the different years of the studies. 
Benign diagnostic biopsy rates were similar across age-groups.
The percentage of cancers with non-operative diagnosis was
significantly higher (P = 0.005) in women aged 65–69 than in
those aged 50–64 for those previously screened within 5 years. 
The positive predictive value (PPV) of recall for assessment
was consistently higher in the older age-group. For women
previously screened within 5 years, the PPV for all cancers for
women 65–69 was 29.0% compared to 15.6% for women 50–64.
For women with a longer screening interval the percentages were
24.3% and 16.5%, respectively. 
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Table 1 Uptake of screening (age groups 50–64 and 65–69) 
Total England 1997–2000 
%%  
Invited uptake Invited uptake 
First invitation 
50–64 48 599 76 1 019 314 73 
65–69 1564 48 
Previous non-attenders 
50–64 25 874 24 519 168 23 
65–69 9628 19 
Previous screen  5 years 
50–64 126 088 91 2 500 751 90 
65–69 23 846 90 
Previous screen > 5 years 
50–64 10 378 58 228 660 54 
65–69 14 937 77 
Total 50–64 210 939 78 4 276 893 76 
65–69 49 975 71 B
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Table 2 Outcome of incident screens 
(i) Women previously screened ≤ 5 years ago
No of women  Referred for  In-situ cancers Invasive cancers Total cancers Benign biopsy Non-operative diagnosis 
screened assessment
No. % No. % No. % No. % No. % No. % of cancers 
50–64 114 394 3913 3.4 139 0.12 472 0.41 611 0.53 62 0.05 488 79.9 
60–64 42 655 1424 3.3 63 0.15 224 0.53 257 0.60 19 0.04 223 86.8 
65–69 21 363 601 2.8 28 0.13 144 0.67 174 0.81 14 0.07 155 89.1 
England 1997–2000 
50–64 2 236 289 83 801 3.7 2105 0.09 9097 0.41 11 447 0.51 1731 0.08 9158 80.0 
60–64 794 481 28 420 3.6 814 0.10 3930 0.49 4835 0.61 546 0.07 3953 81.8 
(ii) Women previously screened > 5 years ago 
No of women  Referred for In-situ cancers Invasive cancers Total cancers Benign biopsy Non-operative diagnosis 
screened assessment
No. % No. % No. % No. % No. % No. % of cancers 
50–64 6070 255 4.2 8 0.13 34 0.56 42 0.69 12 0.20 31 73.8 
60–64 3076 130 4.2 6 0.20 17 0.55 23 0.75 6 0.20 17 73.9 
65–69 11 475 411 3.6 18 0.16 81 0.71 100 0.87 9 0.08 82 82.0 
England 1997–2000 
50–64 122 630 5968 4.9 183 0.15 667 0.54 870 0.71 150 0.12 688 79.1 
60–64 55 707 2663 4.8 94 0.17 365 0.66 466 0.84 61 0.11 365 78.3 
For a few cancers, the invasive status was not known so the total cancers will not always agree with the sum of in-situ and invasive cancers. In all sites combined the percentage of invasive cancers with
size <15 mm was 55% for women aged 65–69, compared with
63% for women 50–64, for women previously screened within 5
years. For women with a longer screening interval the percentages
were 53% and 35% respectively (Table 3). 
Table 4 gives the results for the Nottingham Prognostic Index
(Galea et al, 1992) using the revised formula for cases with
unknown lymph nodes status. The percentages falling into
different prognostic categories in the 2 age-groups were similar. 
Across all sites, the proportion of appointment queries or
changes requested by women aged 65–69 was significantly less
than that for those aged 50–64 (26.4% vs 29.7%, P < 0.01). 
Table 5 shows the overall time the women spent at the screening
unit and the time actually spent screening. The mean overall
screening time and mean time attributable to the screen, at each
of the demonstration sites, were not significantly different
between the 2 age-groups (P = 0.96 overall times, P = 0.10 screen
times). 
The estimated unit cost of an invitation for both age-groups was
£8.37; the cost of a screen was estimated to be £10.78 on a mobile
van and £12.01 at a static unit. On the basis of information
provided by the demonstration sites, it was assumed that East
Sussex, Brighton and Hove screened all women on mobile vans,
Leeds and Wakefield screened 88% of women on mobile vans and
12% at a static unit and that Nottingham screened 72% of women
at a static site and 28% on mobile van. 
The cost of a technical recall screen was assumed to be £11.40.
Across the 3 sites the average proportion of technical recalls was
0.86% for women aged 50–64 years and 0.92% for women aged
65–69 years. 
The estimated cost of an assessment was £53.09. The proportion
of assessed women who had FNA cytology and/or core biopsy was
greater for women aged 65–69 (40.0%) than for women aged
50–64 (31.4%) reflecting the increased PPV in older women.
Whilst the cost of assessing a woman aged 65–69 may therefore be
greater than that for a women aged 50–64, the cost per cancer
detected will remain lower. In the absence of more accurate cost
data, however, the cost of an assessment for both age-groups was
assumed to be the same. The effect of doubling the cost of assess-
ment for women aged 65–69 was addressed in the sensitivity
analysis, but did not alter the main findings. 
The total estimated cost to the breast screening programme of
inviting 100 000 women aged 50–64 and 100 000 women aged
65–69 is shown in Table 6, and the cost per woman invited, per
woman screened and per cancer detected in Table 7. There is little
difference between the 2 age groups in terms of the cost per
woman invited and the cost per woman screened. The total cost to
the programme in terms of invitations, screens and assessments is
slightly (3%) less per 100 000 women invited for women aged
65–69 years compared to women aged 50–64 years. The cost per
cancer detected is 34% less for women aged 65–69 years. The
overall findings remained similar for the sensitivity analyses. 
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Table 3 Size of invasive cancers detected in incident screens (number of cases and % of women screened) 
(i) Women screened ≤ 5 years ago
< 10 mm ≥ 10–15 mm ≥ 15 mm Size not known Total 
No. % No. % No. % No. % No. % 
50–64 146 0.13 150 0.13 171 0.15 5 0.00 472 0.41 
60–64 75 0.18 66 0.15 82 0.19 1 0.00 224 0.53 
65–69 38 0.18 41 0.19 61 0.29 4 0.02 144 0.67 
England 1997–2000 
50–64 2228 0.10 2781 0.12 3986 0.18 102 0.00 9097 0.41 
60–64 997 0.13 1215 0.15 1676 0.21 42 0.01 3930 0.49 
(ii) Women screened > 5 years ago 
< 10 mm ≥ 10–15 mm ≥ 15 mm Size not known Total 
No. % No. % No. % No. % No. % 
50–64 6 0.10 6 0.10 22 0.36 0 0.00 34 0.56 
60–64 1 0.03 5 0.16 11 0.36 0 0.00 17 0.55 
65–69 12 0.10 31 0.27 38 0.33 0 0.00 81 0.71 
England 1997–2000 
50–64 147 0.12 189 0.15 319 0.26 12 0.01 667 0.54 
60–64 80 0.14 107 0.19 170 0.31 8 0.01 365 0.66 
Table 4 Nottingham prognostic index (prevalent and incident screens)
including cancers where the nodes were not sampled 
Good Moderate Poor Not known 
No. % No. % No. % No. % Total 
50–64 411 58 218 31 53 7 25 4 707 
65–69 155 56 90 33 18 7 13 5 276 
Table 5 Comparison of screen times by age group 
Screen time  Overall time 
(minutes:seconds) (minutes:seconds) 
Mean (95% CI) (n) Mean (95% CI) (n) 
50–64 4:16 (4:08–4:23) (n = 534) 17:46 (16:55–18:38) (n = 532) 
65–69 4:02 (3:48–4:16) (n = 151) 17:49 (16:23–19:15) (n = 151) DISCUSSION 
One of the original concerns about inviting older women for
screening was their possible lower uptake. In these demonstration
studies uptake in women aged 65–69 being invited for re-
screening was high, and similar to that for younger women.
Reasons for this may include the fact that the women included
should all have been invited at least once previously within the
NHSBSP and would therefore be accustomed to the idea of routine
screening. This may contrast with earlier studies where many of
the women were receiving their first invitation at an older age.
Hobbs et al (1990) found an uptake of 62.2% in women aged
65–69 compared with 69.3% in those aged 50–64 at prevalent
screen, whilst Horton Taylor et al reported an uptake of 34.5% in
women 65–69 compared with 38.9% in younger women in an
inner city area with low uptake (Horton-Taylor et al, 1996). 
Future national uptake rates might be expected to be even higher
if invitations for older women were to become national policy
because of the accompanying publicity. In the Netherlands, where
women are routinely invited up to age 74, the attendance in
previous attenders was 90.5% in women aged 65–69 and 78.1% in
those aged 70–74, compared with 92.5% in women aged 60–64
(National Evaluation Team for Breast Cancer Screening, 2000). 
For comparison between age-groups and extrapolation to the
screening programme as a whole the results of incident screens are
most appropriate. Observed invasive cancer detection rates were
higher for older women in line with those expected given the
increasing incidence with age. In contrast, detection rates of in-situ
cancers were no higher in the older age-groups. Referral rates for
assessment were lower in older women; this is in contrast to the
Netherlands, which has generally low referral rates, where the rate
at incident screens in women aged 65–69 was 0.46% compared
with 0.31% in those aged 50–64 (Fracheboud et al, 1998),
although the PPV of referral was still higher in the older age-
group. 
Thus in terms of uptake and cancer detection, invitation to
screening would appear to have performed at least equally well
here in women 65–69 as in younger women. Characteristics of
screen-detected tumours in the 2 age-groups support the prediction
that a similar reduction in breast cancer mortality would be
achieved by screening older women to that resulting from
screening women 50–64. Similar findings have been reported from
the Netherlands screening programme (van Dijck et al, 1996). 
Estimates of the cost of screening women aged 65–69 compared
to those aged 50–64 show that the cost per cancer detected is
approximately 34% lower. Our analysis assumes that the unit cost
of an invitation, screen and assessment for a women aged 65–69
was the same as that for a woman aged 50–64. There was no
evidence to suggest that the unit cost of an invitation or screen
would be any more for a woman aged 65–69 compared to a
woman aged 50–64, and indeed the cost of an invitation may well
be less. Doubling the cost of assessment for women aged 65–69
did not alter the main findings. 
Biopsy and treatment costs were not quantified. However, the
results suggested a similar proportion of women invited for
screening would be referred for biopsy in both age-groups. A
greater number of cancers were detected in women aged 65–69
compared to women aged 50–64, implying the total cost associ-
ated with treatment will be higher per 100 000 women invited for
screening for women aged 65–69. Most of these women would,
however, otherwise require treatment for symptomatic disease
within a few years. 
A crude comparison of the average cost per life-year gained can
be made by assuming the same proportion of deaths from breast
cancer is prevented, in women with screen-detected invasive
cancer, regardless of the age-group. The ratio of deaths prevented
in the 50–64 age group to the 65–69 age group is 4:7 (ie. the same
as that of the cancer detection rates). If, for example, the average
life years gained in the 2 age groups are 15 and 8.5 respectively,
the ratio of life years gained is (4/7) × (15/8.5) = 1.01. The
increased cancer detection rate in older women then approximately
balances the reduction in life-years gained, so that cost per life-
year gained in each age-group would be similar. 
These studies were conducted in women aged 65–69; an
extension of the NHSBSP would more logically cover those aged
65–70, so that all women receive 2 additional invitations, and a
proposal for such an extension has recently been announced in the
NHS Cancer Plan with all programmes starting to invite older
women by 2004 (Department of Health, 2000). This is a chal-
lenging expansion that will necessitate additional buildings, equip-
ment and staff. For England as a whole there are 1.35 million
women aged 65–70; extending the invitation system as proposed
Breast screening in women aged 65–69 1293
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Table 6 Total costs attributable to the screening programme per 100 000 women invited 
Age group Cost of invitations Cost of screensa Cost of assessments Total 
(£) (£) (£) (£) 
50–64 837 000 974 497 162 150 1 973 647 
65–69 837 000 933 669 138 533 1 909 202 
aIncludes cost of technical recall screens. 
Table 7 Total cost per woman inviteda, screened and cancer detected 
Age group Total cost per woman invited (£) Total cost per woman screened (£) Total cost per cancer detected (£) 
50–64 19.74 22.36 4124.59 
65–69 19.09 22.54 2702.36 
aCosts associated with invitations, screens and assessments. will result in approximately 450 000 invited each year with
320 000 or more of these attending each year, compared with the
45 000 women aged 65–69 currently self-referring. Extrapolating
from the experience of one of the demonstration sites, this would
require around £13.5 million per annum, including staff costs of an
additional 25 whole time equivalent radiologists and 187 radiogra-
phers and non-staff costs of £5.9 million per annum. This figure
can only be indicative as it is based on one centre and non-staff
costs in particular are known to vary between centres (Johnston
et al, 1996). This is higher than the figure of £8.6 million obtained
using the estimated cost per woman invited derived earlier where
an opportunity cost approach was used to estimate the unit costs,
whereby the resources required for each screening activity were
quantified and valued (Johnston et al, 1996). The latter will not
have included aspects of the programme such as quality assurance
and national co-ordination. Recommended staffing levels have
also increased since the original estimates were derived. The find-
ings relating to the cost differences for women aged 65–69
compared to women aged 50–64 still hold even if the unit cost of a
screen were doubled such that the cost per woman invited is
£27.86 for women aged 65–69 and £29.87 for women aged 50–64
and the total resources required per annum to screen women aged
65–69 is £12.4 million. 
In conclusion, including women up to age 70 in the invitation
system is likely to be as cost-effective as for women aged 50–64,
and no major logistical difficulties with screening older women
were identified. The proposed inclusion of older women in the
invitation system by the NHSBSP over the next 5 years has
considerable workforce implications, which new skill mix
arrangements about to be piloted will help to address. 
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